MarketCapExport financials
Invacare Corporation (IVC)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Invacare Corporation Financial Ratios 2022-2008 | IVC
Brief overview of Invacare Corporation's financial ratios
Current figures are compared with the company's own five-year history for 2015–2022.
The valuation comparison uses P/E 40.49x (median 40.49x), EV/EBITDA 0.53x (median 8.4x), P/S 0.13x (median 0.28x). The current ratio basket stands about 52.1% below the five-year comparison base. Earnings and risk trends should explain the discount.
At the current P/E, inverse earnings yield is 2.5%, a useful bridge between price and business earnings.
End-period return metrics are ROE -25.4%, ROA -2.7%, ROCE -99.2%. Current return ratios are negative, materially weakening the fundamental profile.
The cash conversion cycle increased 150.2 days to 213.6 days, weakening working-capital efficiency.
Valuation takeaway
Invacare Corporation trades below its own history, but weak profitability may explain the discount. Low multiples alone do not prove undervaluation.
Annual Financial Ratios Invacare Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-1.2 | 40.5 | -11.3 | -4.8 | -3.8 | -7.7 | -8.5 | -18.5 | -8.1 | 18.9 | 263.6 | -128.0 | - | - | - |
P/S |
0.1 | 0.3 | 0.4 | 0.3 | 0.2 | 0.6 | 0.3 | 0.4 | 0.4 | 0.5 | 0.3 | 0.3 | - | - | - |
EPS |
-0.5 | 0.1 | -0.8 | -1.6 | -1.3 | -2.3 | -1.3 | -0.8 | -1.8 | 1.0 | 0.1 | -0.1 | 0.8 | 1.3 | - |
EV (Enterprise Value) |
-34.7 M | -5.28 M | 215 M | 721 M | 578 M | 1.06 B | 723 M | 799 M | 816 M | 1.02 B | 1.08 B | 1.15 B | -48.5 M | -37.5 M | -47.5 M |
EBITDA per Share |
-1.78 | -0.21 | 0.75 | 0.15 | -0.08 | -0.78 | -0.02 | 0.32 | -0.87 | 1.15 | 1.22 | 1.22 | 1.14 | 1.27 | - |
EV/EBITDA |
0.5 | 0.7 | 8.4 | 139.9 | -211.1 | -41.5 | -1247.0 | 76.6 | -29.3 | 27.8 | 28.1 | 29.5 | -1.3 | -0.9 | - |
PEG |
-0.01 | 0.05 | -0.02 | -0.01 | -0.01 | -0.01 | 0.1 | 0.3 | 0.22 | 0.01 | -2.02 | 1.12 | - | - | - |
P/B |
0.0 | 0.1 | 0.3 | 0.8 | 0.5 | 1.4 | 0.9 | 1.0 | 0.8 | 0.9 | 0.8 | 0.8 | - | - | - |
P/CF |
-0.4 | -5.5 | 14.6 | 93.9 | -3.6 | -23.0 | -5.5 | -38.4 | -136.5 | -166.0 | 12.6 | 7.0 | - | - | - |
ROE % |
-25.37 | 0.89 | -8.47 | -17.29 | -12.23 | -18.08 | -10.15 | -5.66 | -9.92 | 4.93 | 0.29 | -0.66 | 3.88 | 5.87 | - |
ROA % |
-2.67 | 0.21 | -2.99 | -6.26 | -4.96 | -7.18 | -4.74 | -3.12 | -5.82 | 3.01 | 0.14 | -0.32 | 1.98 | - | - |
ROCE % |
-99.23 | -11.09 | 3.39 | -1.64 | -2.66 | -4.74 | -2.23 | -1.32 | -8.73 | -2.97 | 3.16 | 7.27 | - | - | - |
Current Ratio |
- | - | - | 1.6 | 1.7 | 1.7 | 1.9 | 2.2 | 2.4 | 2.6 | 2.0 | 2.0 | - | - | - |
DSO |
206.4 | 182.1 | 48.3 | 46.5 | 46.1 | 45.7 | 42.7 | 45.2 | 49.3 | 53.0 | 52.7 | 46.9 | - | - | - |
DIO |
82.8 | 74.8 | 71.1 | 68.1 | 64.8 | 67.4 | 62.6 | 62.0 | 61.5 | 64.0 | 65.0 | 54.9 | - | - | - |
DPO |
75.6 | 62.1 | 52.3 | 49.5 | 47.4 | 46.8 | 45.8 | 49.2 | 46.8 | 47.1 | 49.7 | 45.8 | - | - | - |
Operating Cycle |
289.2 | 257.0 | 119.5 | 114.6 | 110.8 | 113.1 | 105.3 | 107.2 | 110.8 | 116.9 | 117.7 | 101.7 | - | - | - |
Cash Conversion Cycle |
213.6 | 194.9 | 67.2 | 65.2 | 63.4 | 66.3 | 59.5 | 58.0 | 64.0 | 69.8 | 68.0 | 55.9 | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Invacare Corporation
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-1.08 | - | -0.92 | -0.62 | -0.69 | 0.06 | -0.65 | -0.31 | -0.31 | -0.15 | -0.21 | -0.48 | 0.02 | -0.56 | -0.24 | -0.38 | -0.42 | -0.04 | -0.36 | -0.5 | -0.43 | -0.54 | -0.57 | -0.72 | -0.52 | -0.54 | -0.15 | -0.36 | -0.27 | -0.09 | -0.24 | -0.26 | -0.23 | -0.29 | -0.47 | -0.43 | -0.56 | -0.18 | 0.5 | -0.39 | 1.1 | -0.23 | 0.09 | -0.06 | 0.26 | -1.1 | 0.4 | 0.33 | 0.23 |
EBITDA per Share |
-0.18 | - | -0.58 | -0.19 | -0.36 | - | -0.35 | 0.14 | 0.14 | - | 0.39 | 0.13 | 0.38 | - | 0.42 | 0.1 | -0.02 | - | 0.2 | 0.03 | -0.03 | - | 0.15 | -0.26 | -0.22 | - | 0.42 | 0.07 | -0.04 | - | 0.46 | 0.14 | 0.03 | - | 0.83 | 0.57 | 0.3 | - | 0.89 | 0.59 | 0.28 | - | 0.91 | 0.61 | 0.3 | - | 0.86 | 0.57 | 0.27 |
ROE % |
-159.67 | -70.04 | -69.15 | -36.26 | -25.20 | -16.22 | -18.64 | -11.35 | -13.04 | -8.99 | -13.52 | -13.86 | -12.20 | -16.40 | -10.69 | -11.39 | -11.85 | -11.23 | -15.06 | -16.07 | -17.30 | -18.08 | -18.08 | -14.90 | -11.83 | -9.52 | -5.98 | -6.49 | -5.70 | -5.32 | -6.35 | -7.24 | -7.69 | -8.98 | -8.18 | -3.28 | -3.12 | 4.96 | 4.65 | 2.69 | 4.31 | 0.25 | -4.16 | -2.79 | -0.94 | -1.04 | 1.84 | 1.52 | 1.19 |
ROA % |
-15.43 | -10.02 | -9.81 | -7.75 | -6.14 | -4.45 | -5.21 | -3.51 | -4.29 | -3.10 | -4.75 | -4.93 | -4.52 | -6.14 | -4.09 | -4.39 | -4.53 | -4.32 | -5.83 | -6.35 | -7.05 | -7.66 | -7.95 | -6.72 | -5.60 | -4.55 | -2.95 | -3.32 | -3.05 | -2.99 | -3.62 | -4.19 | -4.53 | -5.35 | -4.90 | -1.95 | -1.80 | 2.91 | 2.86 | 1.61 | 2.56 | 0.12 | -2.03 | -1.34 | -0.40 | -0.45 | 0.92 | 0.78 | 0.58 |
ROCE % |
-82.80 | -60.06 | -70.39 | -30.38 | -21.60 | -12.82 | -11.93 | -2.34 | 2.00 | 3.25 | 4.01 | 1.77 | 1.23 | -1.87 | -3.30 | -5.82 | -5.68 | -4.40 | -5.75 | -8.01 | -8.87 | -7.65 | -7.09 | -6.97 | -4.43 | -1.82 | -1.78 | -3.52 | -3.16 | -2.01 | 0.04 | -1.18 | -0.87 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DSO |
47.0 | - | 45.8 | 47.6 | 50.7 | 47.0 | 48.2 | 48.8 | 46.3 | 44.3 | 43.7 | 47.4 | 47.4 | 45.5 | 45.5 | 45.9 | 48.4 | 43.8 | 44.6 | 46.6 | 46355.2 | 46.0 | 83663.3 | 230207.0 | 123867.2 | 44.7 | 158024.2 | 178625.0 | 228238.2 | 43.8 | 326817.3 | 348895.5 | 381654.3 | 46.8 | 432594.6 | 51.6 | 55.4 | 52.4 | 312163.9 | 249550.9 | 169781.7 | 57.7 | 138421.9 | 162376.5 | 70597.5 | 56.9 | 38343.7 | 84500.6 | - |
DIO |
81.1 | - | 85.2 | 92.6 | 86.8 | - | 82.4 | 79.9 | 71.9 | - | 88.2 | 87.2 | 70.2 | - | 66.8 | 67.9 | 72.8 | - | 71.0 | 68.5 | 67.9 | - | 75.3 | 80.7 | 76.8 | - | 69.0 | 66.0 | 65.0 | - | 66.6 | 66.5 | 66.0 | - | 63.4 | 64.0 | 66.0 | - | 64.4 | - | - | - | - | - | - | - | - | - | - |
DPO |
66.5 | - | 68.1 | 75.3 | 74.8 | - | 61.4 | 61.0 | 54.1 | - | 59.7 | 64.1 | 52.4 | - | 47.7 | 46.5 | 50.9 | - | 48.4 | 47.7 | 49.5 | - | 42.7 | 48.9 | 49.5 | - | 47.0 | 47.2 | 50.0 | - | 48.0 | 51.5 | 51.5 | - | 47.2 | 48.0 | 49.6 | - | 44.0 | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
128.1 | - | 131.0 | 140.2 | 137.6 | 47.0 | 130.5 | 121.1 | 128.3 | 44.2 | 122.8 | 133.2 | 88.8 | 45.7 | 94278.2 | 89526.9 | 83684.8 | 44.7 | 128613.0 | 80407.6 | 45024.6 | 45.8 | 83728.7 | 233991.9 | 125498.9 | 43.0 | 134405.5 | 143480.5 | 206999.4 | 41.4 | 284963.8 | 290439.4 | 345685.9 | 44.2 | 370359.9 | 44501.8 | 234251.9 | 52.0 | 296813.0 | 232591.3 | 165193.6 | 51.1 | 109275.2 | 126850.9 | 62023.0 | 55.9 | 36204.2 | 81102.6 | - |
Cash Conversion Cycle |
61.7 | - | 62.9 | 64.9 | 62.8 | 47.0 | 69.1 | 64.8 | 70.8 | 44.2 | 65.5 | 70.8 | 62.0 | 45.7 | 94230.4 | 89479.9 | 83633.9 | 44.7 | 128565.8 | 80360.5 | 44975.6 | 45.8 | 83682.8 | 233942.9 | 125449.9 | 43.0 | 134364.2 | 143440.6 | 206953.3 | 41.4 | 284917.5 | 290393.3 | 345637.3 | 44.2 | 370313.5 | 44455.3 | 234203.1 | 52.0 | 296769.1 | 232591.3 | 165193.6 | 51.1 | 109275.2 | 126850.9 | 62023.0 | 55.9 | 36204.2 | 81102.6 | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Invacare Corporation, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Medical devices industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Cytosorbents Corporation
CTSO
|
$ 3.9 | 0.62 % | $ 243 M |  USA |
 |
Delcath Systems
DCTH
|
$ 15.97 | 0.76 % | $ 572 M | USA |
 |
Electromed
ELMD
|
$ 28.23 | 0.11 % | $ 233 M | USA |
 |
Establishment Labs Holdings
ESTA
|
$ 64.17 | 0.74 % | $ 1.9 B |  Costa-rica |
 |
Edwards Lifesciences Corporation
EW
|
$ 86.32 | 1.43 % | $ 50.5 B | USA |
 |
Globus Medical
GMED
|
$ 74.9 | 1.22 % | $ 10.1 B | USA |
 |
Helius Medical Technologies
HSDT
|
$ 2.62 | 1.92 % | $ 57.8 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
$ 16.28 | 2.27 % | $ 1.25 B | USA |
 |
Inogen
INGN
|
$ 5.27 | 1.49 % | $ 140 M | USA |
 |
InMode Ltd.
INMD
|
$ 14.17 | 0.11 % | $ 916 M |  Israel |
 |
Inspire Medical Systems
INSP
|
$ 69.36 | 4.56 % | $ 2.04 B | USA |
 |
IRIDEX Corporation
IRIX
|
$ 0.63 | 2.4 % | $ 10.7 M | USA |
 |
IRadimed Corporation
IRMD
|
$ 86.22 | 0.25 % | $ 1.1 B | USA |
 |
Integer Holdings Corporation
ITGR
|
$ 126.35 | 0.02 % | $ 4.39 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
$ 22.27 | 0.8 % | $ 522 M | USA |
 |
LENSAR
LNSR
|
$ 6.59 | 0.72 % | $ 78.8 M | USA |
 |
Pulmonx Corporation
LUNG
|
$ 1.91 | 0.25 % | $ 77.7 M | USA |
 |
Medtronic PLC
MDT
|
$ 86.29 | 0.03 % | $ 111 B | USA |
 |
MiMedx Group
MDXG
|
$ 4.66 | 0.21 % | $ 689 M | USA |
 |
Myomo
MYO
|
$ 1.56 | 1.27 % | $ 65.3 M | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
$ 0.69 | 5.73 % | $ 44.7 M | Israel |
 |
InspireMD
NSPR
|
$ 0.67 | 0.53 % | $ 43.1 M | Israel |
 |
Orthofix Medical
OFIX
|
$ 9.41 | 4.24 % | $ 373 M |  Curacao |
 |
PAVmed
PAVM
|
$ 3.69 | 0.66 % | $ 2.47 M | USA |
 |
Penumbra
PEN
|
$ 318.34 | 0.02 % | $ 12.4 B | USA |
 |
Insulet Corporation
PODD
|
$ 130.47 | 0.26 % | $ 9.18 B | USA |
 |
Profound Medical Corp.
PROF
|
$ 5.8 | 1.4 % | $ 175 M |  Canada |
 |
Quanterix Corporation
QTRX
|
$ 3.71 | 1.09 % | $ 158 M | USA |
 |
AVITA Medical
RCEL
|
$ 11.73 | 0.17 % | $ 327 M |  Australia |
 |
Sintx Technologies
SINT
|
$ 2.23 | 9.85 % | $ 6.18 M | USA |
 |
Smith & Nephew plc
SNN
|
$ 26.96 | 0.04 % | $ 23.4 B |  Britain |
 |
Sensus Healthcare
SRTS
|
$ 2.99 | 0.65 % | $ 48.8 M | USA |
 |
Stryker Corporation
SYK
|
$ 275.39 | 0.26 % | $ 105 B | USA |
 |
Tactile Systems Technology
TCMD
|
$ 22.29 | 0.24 % | $ 510 M | USA |
 |
TELA Bio
TELA
|
$ 1.15 | 0.81 % | $ 54 M | USA |
 |
TransMedics Group
TMDX
|
$ 83.45 | 1.62 % | $ 2.84 B | USA |
 |
Tandem Diabetes Care
TNDM
|
$ 16.31 | 0.91 % | $ 1.11 B | USA |
 |
Viemed Healthcare
VMD
|
$ 9.1 | 1.32 % | $ 354 M | USA |
 |
Varex Imaging Corporation
VREX
|
$ 18.45 | 0.05 % | $ 764 M | USA |
 |
Vivos Therapeutics
VVOS
|
$ 0.15 | 12.23 % | $ 1.54 M | USA |
 |
Beyond Air
XAIR
|
$ 2.76 | 9.27 % | $ 22.9 B | USA |
 |
Xtant Medical Holdings
XTNT
|
$ 0.36 | 1.59 % | $ 50.2 M | USA |
 |
Zimmer Biomet Holdings
ZBH
|
$ 88.83 | 0.26 % | $ 17.6 B | USA |
 |
Venus Concept
VERO
|
- | - | $ 726 K | USA |
 |
Zynex
ZYXI
|
- | - | $ 21.1 M | USA |
 |
Conformis
CFMS
|
- | - | $ 16.4 M | USA |
 |
Eargo
EAR
|
- | - | $ 10.2 M | USA |
 |
Medigus Ltd.
MDGS
|
- | 10.28 % | $ 55.5 M | Israel |
 |
Cutera
CUTR
|
- | -10.19 % | $ 1.99 M | USA |
 |
Nemaura Medical
NMRD
|
- | -17.8 % | $ 2.74 M | Britain |